Audry Kang, MD
Urology · Gresham, ORNPI 1023466182
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (52.6%), travel and lodging and education — rather than concentrated in one kind of arrangement. 26 manufacturers reported payments, led by Coloplast at 32.9% of the total. Reporting peaked in 2023 at $1,776 and has fallen 78.1% since, to $389 in 2024.
Across 81 payments — averaging $49.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Coloplast$1K
- Procept Biorobotics Corporation$551
- Teleflex LLC$529
- Boston Scientific$240
- AbbVie$221
- Pfizer$162
- plus $988 from 20 others
What the payments were for
- Travel & lodging$1,80945%
- Food & beverage$2,10653%
- Education$932%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Coloplast | 13 | $1,319 |
| Procept Biorobotics Corporation | 3 | $551 |
| Teleflex LLC | 3 | $529 |
| Boston Scientific | 5 | $240 |
| AbbVie | 11 | $221 |
| Pfizer | 4 | $162 |
| Astellas Pharma US Inc | 6 | $130 |
| Urogen Pharma, Inc. | 4 | $103 |
| Tolmar, Inc. | 4 | $102 |
| Angiodynamics, Inc. | 1 | $85 |
| Sumitomo Pharma America, Inc. | 1 | $78 |
| Accord Healthcare, Inc. | 2 | $61 |
| Endo Pharmaceuticals Inc. | 4 | $60 |
| Progenics Pharmaceuticals, Inc. | 2 | $57 |
| Bayer | 3 | $55 |
| Alnylam Pharmaceuticals Inc. | 2 | $48 |
| Olympus America Inc. | 2 | $31 |
| Myriad Genetic Laboratories, Inc. | 2 | $31 |
| Dendreon Pharmaceuticals LLC | 1 | $31 |
| 180 Medical, Inc. | 1 | $23 |
| Johnson & Johnson | 1 | $22 |
| Merck | 1 | $18 |
| Baxter Healthcare | 1 | $17 |
| Medtronic | 1 | $15 |
| Smith+Nephew | 1 | $14 |
| Travere Therapeutics, Inc. | 2 | $8 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TITAN$1,040
- AquaBeam Robotic System$522
- UroLift$502
How this compares
$4,008 in reported general payments places this provider in the 75th percentile of 153 urology providers in Oregon.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GemtesaVibegron | 111 | $90,364 |
| MyrbetriqMirabegron | 97 | $75,765 |
| Mirabegron ErMirabegron | 17 | $7,646 |
| Methenamine Hippurate | 45 | $6,691 |
| Estradiol | 60 | $5,380 |
| Tamsulosin Hcl | 238 | $3,609 |
| Oxybutynin Chloride ErOxybutynin Chloride | 84 | $1,511 |
| Solifenacin Succinate | 31 | $1,153 |
| Cephalexin | 80 | $963 |
| Finasteride | 59 | $737 |
| NitrofurantoinNitrofurantoin Macrocrystal | 13 | $622 |
| Trimethoprim | 12 | $529 |
| Gentamicin Sulfate | 18 | $348 |
| Phenazopyridine Hcl | 11 | $190 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 40 | $187 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Gemtesa | $78 | $90,364111 claims |
| Astellas Pharma US IncMyrbetriq | $130 | $75,76597 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 153 urology providers in Oregon.
Other urology in Gresham
- Shammai RockoveGresham$8K
- Brian BlairGresham$5K
- Melanie Crites-BachertGresham$3K
- Bryan MehlhaffSpringfield$1M
- Lance MarrPortland$323K
- Matt AshleyBend$212K
- da David JiangPortland$65K
- Kim ThaiMedford$57K
- Kevin KrughoffSpringfield$54K
- Kyle GillisClackamas$51K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.